Genfit SA (GNFT) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Genfit SA has announced that their diagnostic technology, NIS2+®, is now recommended as a crucial tool for detecting at-risk MASH in the latest European Clinical Practice Guidelines. This endorsement, which underscores the tool’s potential in identifying patients for emerging treatments, comes as non-invasive methods gain preference over traditional liver biopsies. NIS2+® stands out as the only blood-based panel cited for this purpose amidst growing appreciation for less invasive diagnostic options.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
